Mexico · Delayed Price · Currency is MXN Genomma Lab Internacional Earnings Call Transcripts
Fiscal Year 2026
-
Net sales declined 4.9% year-over-year due to FX headwinds and weak Mexican consumption, but gross margin expanded and LATAM delivered strong growth. Management expects margin pressure through Q3 as investments defend market share, with recovery in Mexico anticipated later in 2026.
Fiscal Year 2025
-
2025 saw a deliberate inventory normalization in Mexico, leading to lower sales but resilient margins and strong cash flow. Productivity gains and disciplined cost management support a positive 2026 outlook, with gradual top-line recovery and EBITDA margin guidance of 23%-23.5%.
-
Sales declined due to FX and weak seasons, but EBITDA margin remained strong at 23.7% as cost efficiencies offset top-line pressure. Growth initiatives, innovation, and digital expansion are expected to drive recovery by 2026, with productivity savings reinvested to support this plan.
-
Q2 2025 saw modest sales growth, strong EBITDA margin expansion, and a 65% increase in free cash flow, despite currency headwinds and a weak beverage season in Mexico. Outlook for 2025 is cautious, but gradual growth is expected in 2026, supported by innovation, distribution expansion, and digital initiatives.
-
Q1 2025 saw 5% sales growth, strong profitability, and robust free cash flow, with margin expansion driven by productivity gains. Strategic investments target midterm low-teens sales growth and a stable 24% EBITDA margin, despite macro headwinds and category-specific challenges.
Fiscal Year 2024
-
Q4 and full year 2024 saw double-digit sales and profit growth, with EBITDA and net income surging, margins expanding, and record free cash flow. Growth initiatives and reinvestment of productivity gains are set to accelerate future performance, with stable dividends and low leverage maintained.
-
Q3 2024 saw double-digit sales and profit growth, margin expansion, and record cash flow, driven by strong performance in Mexico, the US, and Argentina. Productivity initiatives, brand acquisitions, and disciplined capital allocation support continued growth and margin improvement.
-
Q2 2024 saw robust profitability and margin expansion, with net income up 50.1% and EPS up 53.1% year-over-year. Strategic M&A, productivity gains, and strong segment performance in Mexico and the U.S. offset macro headwinds and FX volatility.